Printer Friendly

Giant congenital melanocytic nevus responds to trametinib.


A GIANT CONGENITAL MELANOCYTIC NEVUS (GCMN) in a 7-year-old girl was effectively treated with the MEK inhibitor trametinib, according to a case report published in Pediatrics.

The nevus covered most of her back and much of her torso and had thickened significantly over the years since initial presentation to the point of disfigurement, even invading the fascia and musculature of the trunk and pelvis, reported Adnan Mir, MD, PhD, of the University of Texas Southwestern Medical Center, Dallas, and his coauthors. She presented with intractable pruritus and pain that interfered with sleep and responded minimally to treatments.

There are few if any effective treatments for GCMN. Considering general theories of the mechanism of GCMN, the patient's health care team decided to try a 0.5-mg daily dose of trametinib. Her pruritus and pain resolved completely, and after 6 months of treatment with trametinib, repeat MRI "revealed decreased thickening of the dermis and near resolutions of muscular invasion." According to the patient's family, her quality of life improved dramatically.

SOURCE: Mir A et al. Pediatrics. 2019;143(3):e20182469.


COPYRIGHT 2019 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:PEDIATRICS
Author:Palmer, Christopher
Publication:Dermatology News
Date:May 1, 2019
Previous Article:Don't miss baby scabies.
Next Article:Managing duration, severity can improve scar repair rate.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |